BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37992258)

  • 1. Rate of Pathogenic Germline Variants in Patients With Lung Cancer.
    Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
    JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
    Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended gene panel testing in lobular breast cancer.
    van Veen EM; Evans DG; Harkness EF; Byers HJ; Ellingford JM; Woodward ER; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
    Fam Cancer; 2022 Apr; 21(2):129-136. PubMed ID: 33763779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients.
    Satake T; Kondo S; Tanabe N; Mizuno T; Katsuya Y; Sato J; Koyama T; Yoshida T; Hirata M; Yamamoto N
    Cancer Res Commun; 2023 Nov; 3(11):2302-2311. PubMed ID: 37916805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
    Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A
    Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
    Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
    Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline Testing of Patients With Non-small Cell Lung Cancers Demonstrating Incidentally Uncovered BRCA2 Apparent Pathogenic Germline Variants.
    Sorscher S
    Clin Lung Cancer; 2022 Nov; 23(7):e405-e407. PubMed ID: 35977876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer.
    Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D
    Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.
    Rebhan K; Stelzer PD; Pradere B; Rajwa P; Kramer G; Hofmann B; Resch I; Yurdakul O; Laccone FA; Bujalkova MG; Smogavec M; Tan YY; Ristl R; Shariat SF; Egger G; Hassler MR
    World J Urol; 2023 Aug; 41(8):2091-2097. PubMed ID: 37528288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.
    Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H
    Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
    Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME
    JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
    Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
    Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.
    Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T
    Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer.
    Kumari N; Singh RK; Mishra SK; L R; Mohindra S; Krishnani N
    Pathol Res Pract; 2021 Jan; 217():153309. PubMed ID: 33341547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
    Singhal D; Hahn CN; Feurstein S; Wee LYA; Moma L; Kutyna MM; Chhetri R; Eshraghi L; Schreiber AW; Feng J; Wang PP; Babic M; Parker WT; Gao S; Moore S; Das S; Thomas D; Pattnaik S; Brown AL; D'Andrea RJ; Poplawski NK; Thomas D; Scott HS; Godley LA; Hiwase DK
    Leukemia; 2021 Nov; 35(11):3245-3256. PubMed ID: 33850299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.
    Hutchcraft ML; Zhang S; Lin N; Pickarski JC; Belcher EA; Wei S; Bocklage T; Miller RW; Villano JL; Cavnar MJ; Kim J; Arnold SM; Ueland FR; Kolesar JM
    JCO Precis Oncol; 2024 Jan; 8():e2300266. PubMed ID: 38295319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Variants in Patients With a Family History of Pancreatic Cancer: Impact of Multigene Panel Testing.
    Zhu H; Welinsky S; Soper ER; Brown KL; Abul-Husn NS; Lucas AL
    Pancreas; 2021 Apr; 50(4):602-606. PubMed ID: 33939675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in
    Larionov A; Fewings E; Redman J; Goldgraben M; Clark G; Boice J; Concannon P; Bernstein J; Conti DV; The Wecare Study Collaborative Group ; Tischkowitz M
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Universal Germline-Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision-Making.
    Shelton C; Ruiz A; Shelton L; Montgomery H; Freas K; Ellsworth RE; Poll S; Pineda-Alvarez D; Heald B; Esplin ED; Nielsen SM
    Ann Surg Oncol; 2024 Jan; 31(1):325-334. PubMed ID: 37814187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.